Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®)

Assessment Status Rapid Review complete
Drug Bictegravir/emtricitabine/tenofovir alafenamide
Brand Biktarvy®
Indication Treatment of adults infected with HIV-1 without any known mutations associated with resistance to the individual components.
Assessment Process
Rapid review commissioned 30/04/2018
Rapid review completed 07/06/2018
Rapid review outcome Full pharmacoeconomic assessment not recommended. The NCPE recommends that Biktarvy® not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.

The HSE has approved reimbursement following confidential price negotiations December 2018.